TMS Maintenance Protocols: Booster Sessions After Remission

Maintenance protocols after a successful acute TMS course are not standardized. No single maintenance schedule is FDA-cleared, and the Clinical TMS Society consensus explicitly acknowledges that continuation strategy is determined case-by-case by the treating psychiatrist.¹ Three clinical models are seen in routine practice — no maintenance (medication management and psychotherapy alone), scheduled tapering boosters at decreasing frequency, and symptom-triggered boosters initiated when early-relapse warning signs appear. This article describes the three models, the predictors that push a patient toward more intensive maintenance, the option of full re-induction after relapse, and the insurance considerations that shape what is practical.

Why maintenance is on the clinical agenda at all

Acute TMS produces durable response in a substantial fraction of patients, but not all. In a 24-week observational follow-up of patients who had responded to acute rTMS, roughly 37.5% met relapse criteria by the end of the period, with maintenance strategies reducing that rate.² Subsequent long-term registry and trial data have largely confirmed the same gradient — sustained response in the majority, partial loss of effect in a meaningful minority — with continuation rTMS associated with longer time-to-relapse in the patients studied.³⁴

This relapse profile is not unique to TMS. The same gradient is seen with antidepressants and with structured psychotherapy in patients with recurrent major depressive disorder; durable remission in a chronic relapsing illness is the exception, not the rule. The clinical question is therefore not whether the depression can recur after acute TMS — it can — but which patients warrant a continuation strategy, and which strategy is appropriate.

The three maintenance models in clinical practice

Model 1 — No maintenance

Some patients enter sustained remission after the acute course and remain stable through routine medication management and psychotherapy alone, without scheduled booster sessions. The treating psychiatrist makes the call based on the patient's response trajectory (rapid and complete versus slow and partial), prior episode history, and the stability of the surrounding pharmacotherapy and psychosocial environment. The patient is not discharged; they return to routine outpatient psychiatric follow-up, and the TMS service stays available for re-induction if needed.

This model is appropriate for first-episode or low-recurrence patients with full remission at the end of the acute phase and well-controlled risk factors. The evidence base does not support scheduled maintenance for every TMS responder, and over-treating low-risk patients carries both opportunity cost and authorization friction.

Model 2 — Scheduled tapering boosters

A common pattern in clinics that use scheduled maintenance is a stepped-down booster calendar following the acute taper: one session per week for 4 weeks, then one every 2 weeks for 8 weeks, then monthly for 6 months, with reassessment at each step-down. Some clinics use a more aggressive tapering schedule (faster step-down to monthly); others extend the monthly phase to twelve months in patients with multiple prior episodes. The Philip and colleagues maintenance trial documented that scheduled continuation rTMS was associated with longer time-to-relapse than observation alone in responders to acute treatment.³

Scheduled boosters are most often offered to patients with documented relapse history after prior non-TMS treatments, incomplete remission at acute end, or persistent residual symptoms. The schedule is a planning starting point — the treating psychiatrist adjusts frequency based on serial rating-scale data and the patient's clinical course.

Model 3 — Symptom-triggered boosters

In this model, no booster sessions are pre-scheduled. The patient returns to the clinic at the first signs of recurrence — PHQ-9 drift, sleep disturbance, anhedonia, return of cognitive slowing — and a short booster course is delivered before a full relapse develops. The model requires two operational elements: patient self-monitoring with a validated rating scale (PHQ-9 weekly or biweekly is standard) and a low-friction re-entry pathway at the clinic, so the patient is not waiting weeks for a re-evaluation appointment when sub-clinical recurrence is detected.

Symptom-triggered maintenance is appropriate for patients who are reliable self-reporters, have a clearly established prodrome (recognizable early-warning signs from prior episodes), and can re-present quickly when those signs appear. It minimizes session burden and authorization friction at the cost of requiring active engagement from the patient between treatments.

What predicts a need for maintenance

The clinical decision about which model fits a given patient turns on a small number of predictors, drawn from the depression-recurrence literature and from the TMS-specific maintenance evidence:

• History of multiple prior depressive episodes — the single largest factor. Patients with three or more lifetime episodes of major depressive disorder carry the highest recurrence risk and are most likely to benefit from a scheduled maintenance model.
• Incomplete remission at acute end — response (≥50% reduction on a validated scale) without full remission (PHQ-9 < 5 or HAM-D < 7) at the end of the acute course is associated with higher early-relapse risk than full remission.
• Persistent residual symptoms — sub-syndromal depression at acute end (low-grade anhedonia, residual sleep disturbance, persistent cognitive complaints) predicts shorter time-to-relapse and warrants closer follow-up.
• Inability to maintain therapeutic-dose pharmacotherapy — patients who cannot tolerate or adhere to standing antidepressant therapy lose one of the standard relapse-prevention rails and may benefit from scheduled boosters to compensate.
• High-stress life circumstances at the time of the acute course — ongoing major stressors (job loss, caregiving demand, bereavement) that did not resolve during acute treatment increase recurrence risk.

These predictors are weighed together rather than scored mechanically. A patient with a single moderate-severity episode, full remission at acute end, stable pharmacotherapy, and a calm psychosocial environment is a candidate for Model 1. A patient with five prior episodes, incomplete remission, and ongoing job stress is more likely to be offered Model 2 or a hybrid of Model 2 and Model 3.

Re-induction: when relapse occurs despite maintenance

When a patient relapses despite a maintenance strategy — or after a long off-treatment period without maintenance — a full re-induction course is clinically reasonable and often effective. Re-induction means an acute-phase re-stimulation course on the same parameters as the original acute treatment: five days per week for four to six weeks, with motor-threshold remapping at the first session. Mantovani and colleagues documented sustained response with re-treatment for relapse in patients with treatment-resistant depression, and the broader long-term TMS literature supports re-induction as a standard option after loss of response.⁵⁴

Re-induction is not equivalent to indefinite scheduled maintenance. It is a discrete clinical decision made when symptoms have returned to a level that warrants acute-phase treatment intensity. The patient and treating psychiatrist agree on response criteria (typically a PHQ-9 or HAM-D threshold) and on a plan for what follows the re-induction course — often a transition to Model 2 or Model 3 maintenance after the second acute phase.

Insurance reality: maintenance is often a separate authorization

Maintenance TMS is frequently not covered by the initial prior authorization that approved the acute course. Coverage determinations for TMS are governed by Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors — there is no National Coverage Determination — and commercial payer policies generally follow a similar structure.⁶ Most LCDs and commercial policies authorize a defined acute-phase session count plus a taper; maintenance sessions typically require a separate continued-treatment authorization supported by rating-scale evidence of need.

The practical workflow at most clinics:

• Some payers approve scheduled maintenance from the start when the patient meets specific recurrence-history criteria documented in the original prior-auth.
• Many payers require documented relapse or sub-clinical recurrence before authorizing additional sessions, which fits the symptom-triggered (Model 3) model more readily than the scheduled-taper (Model 2) model.
• Re-induction after relapse is typically authorized as a new acute course when the diagnostic and severity criteria of the original authorization are re-met.

The clinic's insurance team prepares the continued-treatment authorization using serial PHQ-9 (or HAM-D, or BDI) data and a letter of medical necessity from the treating psychiatrist. Outcomes vary by payer and by the strength of the documented relapse-risk profile.

What the patient does between treatments

Maintenance — including the no-maintenance Model 1 — is not a passive period. Three patient-side elements carry the relapse-prevention work between any scheduled sessions:

• Continue medication management with the treating psychiatrist (not only with the TMS provider). Standing antidepressant therapy at therapeutic dose, when tolerated, is the standard pharmacologic backbone of relapse prevention.
• Continue psychotherapy where indicated. Evidence-based psychotherapy (cognitive behavioral therapy, interpersonal psychotherapy, or behavioral activation) provides a complementary relapse-prevention rail that is independent of the TMS effect.
• Use serial PHQ-9 self-monitoring (weekly or biweekly, often via the clinic's app or paper form) so trajectory is documented in real time rather than reconstructed at the next appointment. Sub-clinical drift is easier to detect on a chart than in retrospective recall, and documented drift is what supports a continued-treatment authorization.

The instruction patients hear most often is the simplest one: return to the clinic at the first signs of recurrence, not after a full relapse has set in. Early re-entry preserves more clinical options and a stronger insurance position than waiting until function has measurably declined.

Key takeaways

• No maintenance TMS schedule is FDA-cleared. Clinical practice ranges across three models: no maintenance, scheduled tapering boosters, or symptom-triggered boosters.¹
• Approximately 37.5% of acute-TMS responders met relapse criteria by 24 weeks in an early observational cohort, with maintenance strategies associated with reduced relapse — the same gradient seen with antidepressants and psychotherapy in recurrent depression.²
• The strongest predictors of needing scheduled maintenance are multiple prior episodes, incomplete remission at acute end, persistent residual symptoms, inability to maintain pharmacotherapy, and high-stress life circumstances at the time of the acute course.
• Full re-induction — an acute-phase re-stimulation course on the original parameters — is clinically reasonable and often effective when a patient relapses despite maintenance or after a long off-treatment period.⁵
• Maintenance TMS is frequently a separate insurance authorization, often requiring documented sub-clinical recurrence or relapse to approve continued sessions; the no-NCD, LCD-driven coverage framework is what shapes that workflow.⁶
• Between treatments, patients continue medication management, psychotherapy where indicated, and serial PHQ-9 self-monitoring — and return at the first signs of recurrence rather than waiting for full relapse.

Patients in Anaheim, Orange County, and the broader 30-mile radius who have completed an acute TMS course and are weighing what comes next can review the clinic's approach to candidacy, protocol, and continuation on the TMS therapy page, including how maintenance is handled for patients with treatment-resistant depression. For patients considering re-induction or a scheduled maintenance plan, the clinic's team confirms the insurance verification details — whether the existing authorization covers maintenance or a continued-treatment authorization is required — before any additional sessions are scheduled.

Sources / Further reading